RxDoctor Payments Data

Darren Wohl, MD

Gastroenterology · Mebane, NCNPI 1649289836

Payments from drug & device makers

$7,618in general payments, 2019–2025

Across 371 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$911
  • Boston Scientific$862
  • Gilead$800
  • Johnson & Johnson$596
  • Takeda Pharmaceuticals U.S.A., Inc.$510
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$3304%
  • Food & beverage$7,04692%
  • Gifts$2413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,618 in reported general payments places this provider in the 70th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$39,722
Medicare patients
167
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide57$36,906
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates196$12,998
Dexlansoprazole DrDexlansoprazole16$5,701
Budesonide DrBudesonide16$1,984
Pantoprazole Sodium172$1,790
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl46$671
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$529
Dicyclomine Hcl16$525
Esomeprazole Magnesium19$466
Omeprazole27$455
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg19$384
Nadolol18$295
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl13$191
Ondansetron OdtOndansetron15$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,954$36,90657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Mebane

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →